Archive for the ‘Acadia Pharmaceuticals Inc’ Category

Acadia Pharmaceuticals Inc.

September 22nd, 2014 | Posted in 2014, Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc., San Diego, received provisional FDA approval for its trade name Nuplazid for pimavanserin. Nuplazid is a selective serotonin inverse agonist and will represent the first in a new class of drug to treat psychosis.

Acadia Pharmaceuticals

April 30th, 2013 | Posted in 2013, Acadia Pharmaceuticals Inc

Reported recently that it will NOT need to run a second late-stage trial of its drug Pimavanserin, a treatment for psychosis associated with Parkinson’s disease.  Acadia said that the FDA agreed that results from Acadia’s previous clinical trials and other clinical data are enough to support a filing for marketing approval, which Acadia plans to […]

Acadia Pharmaceuticals Inc

October 29th, 2010 | Posted in Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc., received $8.75-million to continue clinical trials of its Parkinson’s disease drug under agreement with Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International Inc.  Under the agreement, Acadia regained all rights to the drug, Primavanserin, and will continue Phase Three Clinical Trials of the drug as a treatment for Parkinson’s […]